Effectiveness and Toxicity Burden of Pembrolizumab in Combination With Neoadjuvant Chemotherapy for Stage II/III Triple Negative Breast Cancer: A Real-World Analysis From Alberta, Canada

OBJECTIVES: The KEYNOTE-522 trial demonstrated improved pathologic complete response (pCR) and long-term survival outcomes by adding pembrolizumab to neoadjuvant anthracycline and taxane (A-T) plus carboplatin in patients with stage II/III triple-negative breast cancer (TNBC). We evaluated early effectiveness and toxicity burden of adding pembrolizumab and carboplatin to neoadjuvant A-T in patients with stage II/III TNBC. METHODS: We included all patients in Alberta with stage II/III TNBC from November 2020 to November 2023, treated with either neoadjuvant A-T or the KEYNOTE-522 regimen, and who underwent surgical resection by June 1, 2024. Our primary outcome was pCR, while secondary outcomes included rates of breast-conserving surgery (BCS), axillary lymph node dissection (ALND), toxicity burden during the neoadjuvant phase, and receipt/type of adjuvant therapy. Propensity score matching (PSM) was conducted to account for baseline differences between groups. RESULTS: A total of 248 patients were included (110 A-T and 138 KEYNOTE-522). Before PSM, the KEYNOTE-522 group had higher rates of pCR (64% vs. 32%; P<0.001) and BCS (57% vs. 42%; P=0.022) with lower rates of ALND (15% vs. 40%; P<0.001). The KEYNOTE-522 group had more emergency department visits (47% vs. 31%, P=0.010) and hospitalizations (23% vs. 6%, P<0.001). After PSM, baseline characteristics between groups were balanced, and differences in effectiveness and toxicity burden outcomes persisted. Within the KEYNOTE-522 group, 70% had postoperative pembrolizumab. CONCLUSIONS: Proportions of pCR and BCS were higher, and ALND lower, in KEYNOTE-522 treated patients with stage II/III TNBC, even after PSM. Future evaluation is needed to determine the real-world impact of the KEYNOTE-522 regimen on recurrence and survival.

Authors

Institutions

Publication Details

Journal
American Journal of Clinical Oncology
Published
2026-11-12
DOI
https://doi.org/10.1097/coc.0000000000001399
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effectiveness and Toxicity Burden of Pembrolizumab in Combination With Neoadjuvant Chemotherapy for Stage II/III Triple Negative Breast Cancer: A Real-World Analysis From Alberta, Canada

Kaiden Jobin, Malek Bassam Hannouf, Sasha Lupichuk, Ammara Naseer et al.
American Journal of Clinical Oncology
Breast Cancer Treatment Studies
article

Effectiveness and Toxicity Burden of Pembrolizumab in Combination With Neoadjuvant Chemotherapy for Stage II/III Triple Negative Breast Cancer: A Real-World Analysis From Alberta, Canada

Kaiden Jobin, Malek Bassam Hannouf, Sasha Lupichuk, Ammara Naseer, Agnes Ho, Shiva Bahmanyar
article en

Abstract

OBJECTIVES: The KEYNOTE-522 trial demonstrated improved pathologic complete response (pCR) and long-term survival outcomes by adding pembrolizumab to neoadjuvant anthracycline and taxane (A-T) plus carboplatin in patients with stage II/III triple-negative breast cancer (TNBC). We evaluated early effectiveness and toxicity burden of adding pembrolizumab and carboplatin to neoadjuvant A-T in patients with stage II/III TNBC. METHODS: We included all patients in Alberta with stage II/III TNBC from November 2020 to November 2023, treated with either neoadjuvant A-T or the KEYNOTE-522 regimen, and who underwent surgical resection by June 1, 2024. Our primary outcome was pCR, while secondary outcomes included rates of breast-conserving surgery (BCS), axillary lymph node dissection (ALND), toxicity burden during the neoadjuvant phase, and receipt/type of adjuvant therapy. Propensity score matching (PSM) was conducted to account for baseline differences between groups. RESULTS: A total of 248 patients were included (110 A-T and 138 KEYNOTE-522). Before PSM, the KEYNOTE-522 group had higher rates of pCR (64% vs. 32%; P<0.001) and BCS (57% vs. 42%; P=0.022) with lower rates of ALND (15% vs. 40%; P<0.001). The KEYNOTE-522 group had more emergency department visits (47% vs. 31%, P=0.010) and hospitalizations (23% vs. 6%, P<0.001). After PSM, baseline characteristics between groups were balanced, and differences in effectiveness and toxicity burden outcomes persisted. Within the KEYNOTE-522 group, 70% had postoperative pembrolizumab. CONCLUSIONS: Proportions of pCR and BCS were higher, and ALND lower, in KEYNOTE-522 treated patients with stage II/III TNBC, even after PSM. Future evaluation is needed to determine the real-world impact of the KEYNOTE-522 regimen on recurrence and survival.

American Journal of Clinical Oncology
University of Calgary (CA), Arthur J.E. Child Comprehensive Cancer Centre (CA)
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon